Foundation For Sarcoidosis Research’s Post

Why include Poland in your #clinicaltrials #clinicalresearch ? Poland is regarded as one of the largest clinical trials markets in CEE/CIS as the ninth-most populous country in Europe, with a population of approximately 38 million people and a total of 413 clinical trials initiated between 1 June 2022 and 1 June 2023. According to data from clinicaltrials.gov, the largest number of clinical trials were conducted in oncology (86), followed by cardiology (50), dermatology (40), and gastroenterology (37). Most trials are in Phase 3 (34%). International sponsors conduct 73% of all ongoing clinical trials. So what do you gain from this? To begin with you get access to expert, experienced investigators and typically a higher than average patient enrolment through the centralized healthcare system and motivated and informed patient pool. Please contact me to find out more about these and other benefits that could be utilized by you for your trial.

An #FSPmodel for today’s demands and tomorrow’s opportunities Modern clinical studies require increasingly responsive solutions. TFS HealthScience provides fit-for-purpose FSP outsourcing solutions uniquely tailored to each customer’s needs with a fully integrated and dedicated team to offer enhanced quality, flexibility, and sustained efficiencies. With teams based in 17 countries, we strategically support both international and local sponsors enabling them to expand their reach and supplement their projects with selected services to meet their requirements at any phase of the study. For customers that require specialized therapeutic or special population expertise, TFS has a wide range of experience in the areas of hematology and oncology, dermatology, immunology & inflammatory diseases, ophthalmology, internal medicine, and neurology as well as rare diseases and pediatrics, among others. Dedicated Strategic Partner #committed to every aspect of your drug development journey TFS HealthScience provides a client-centric FSP solution that enables our partners to focus on core product development. We are prepared to work alongside you to provide fit-for-purpose solutions through your drug-development journey, offering a customized outsourcing model. TFS HealthScience is known for gaining an in-depth knowledge of our customer’s products, procedures, and systems that, together with the seamless integration of our therapeutic and operational expertise, ensure our partners benefit from embedded team optimization and cost savings. #tfshealthscience #tfscro #tfssolutions

I am thrilled to share with you our new Meta-analysis "Accuracy of Computer-aided Diagnosis in Colonoscopy Varies According to Polyp Location: A Systematic Review and Meta-analysis", published in Clinical Gastroenterology and Hepatology. The study investigated the impact of polyp location on the diagnostic performance of computer-aided diagnosis (CADx) systems during real-time colonoscopy. 🔍 Key Findings: - Data derived from the optical diagnosis 7,782 polyps (≤5mm) from 11 studies. - CADx specificity was significantly lower in the proximal colon compared to the distal colon (62% versus 85%; RR 0.74, 0.72-0.84). - Sensitivity was similar (89% vs 87%, RR 1.00, 0.97-1.03). The NPV (64% versus 93%, RR 0.71, 0.64-0.79) and accuracy (81% vs 86%, RR 0.95, 0.91-0.99) were significantly lower in the proximal than distal colon, while PPV was higher in the proximal colon (87% vs 76%, RR 1.11, 1.06-1.17). 📌 Conclusion: - The diagnostic performance of CADx for polyps ≤5 mm in the proximal colon is inadequate, exhibiting significantly lower specificity compared to its performance for distal polyps. - While current CADx systems are suitable for use in the distal colon, they should not be employed for proximal polyps ≤5 mm until more performant systems are developed specifically for these lesions. 🔗 Read The Full Article: https://lnkd.in/dAc3WbMZ Tommy Rizkala Cesare Hassan Yuichi Mori Marco Spadaccini Giulio Antonelli Evelien Dekker Britt Houwen Oliver Pech Sebastian Baumer Emanuele Rondonotti Franco Radaelli James Weiquan Li Daniel von Renteln Masashi Misawa Roberta Maselli Silvia Carrara Alessandro Fugazza Antonio Facciorusso Antonio Capogreco Kareem Khalaf Harsh Patel Prateek Sharma Douglas Rex Alessandro Repici #AIinHealthcare #Artificialintelligence #Gastroenterology #Endoscopy #Colorectalcancer #Medicalresearch #SystematicReview

🧬 The RESPINE Study - the first prospective, multicenter, randomized, placebo-controlled clinical trial investigating the efficacy of ex-vivo expanded, allogenic, bone marrow-derived, mesenchymal stromal cells (MSCs) for chronic low back pain of suspected discogenic origin. 🌏 RESPINE is a groundbreaking clinical trial conducted across four countries - France, Germany, Italy, and Spain - that our team just published in the Annals of the Rheumatic Diseases, the official scientific journal of the EULAR - European Alliance of Associations for Rheumatology, and one of the highest-impact Q1 journals in the field of medicine, with an Impact Factor of 20.3. RESPINE was made possible through funding from the European Union’s Horizon 2020 Research and Innovation Program. 🔬 RESPINE pushes the boundaries of Orthobiologics and Regenerative Medicine for Interventional Spine Care. It offers essential insights into the complexity of MSC therapies, laying the groundwork for the future of biological treatments for spine disorders. Our clinical trial would not have been possible without the expertise and experience of Dr. Robert Soler Rich MD, PhD and the extraordinary team at ITRT - Instituto de Terapia Regenerativa Tisular, in Barcelona. 📚 While the journey ahead in our field remains vast, we believe our clinical trial is a key step forward, offering a foundation that will help shape and guide future research and innovations in spine care, specifically in our ability to treat chronic low back pain of suspected discogenic origin. 📄 We published RESPINE in an Open-Access format, as we believe all Science should be. Our article can also be freely downloaded from the Annals of the Rheumatic Diseases (BMJ) website at: https://lnkd.in/dMcsEfiS #chronicpain #interventionalpainmanagement #orthobiologics #painmedicine #regenerativemedicine #spine

For today's radiology poster, I decided to focus on an interesting topic: renal cell carcinomas. Of course, this topic is vast and can include various pathologies. Due to that, I am primarily focusing on three of them: - Clear cell renal carcinoma (ccRC) - Papillar renal cell carcinoma (pRC) - Chromophobe renal cell carcinoma(cRC) Renal cell carcinomas are considered the eighth most prevalent malignancy in adults, constituting 2% of all cancer types, and represent 80-90% of primary malignant neoplasms originating in the adult kidney. Patients typically manifest symptoms of renal cell carcinomas between the ages of 50 and 70, with a slight male predominance highlighted in the literature. The classic clinical presentation is often summarized as a triad comprising gross hematuria, flank pain, and a sometimes noticeable mass in the flank region (even so, this is less frequent). However, in the context of modern clinical practice, nearly half of all renal cell carcinomas are detected incidentally during imaging procedures conducted for no specific reason. As I previously mentioned, RCC originates from the tubular epithelium and is categorized into various distinct histopathological types. One of the predominant types is clear cell renal carcinoma (ccRC), which constitutes 70 to 80% of cases. This tumor type is notably vascular and originates from the proximal convoluted tubules. Another type, known as papillary renal cell carcinoma, represents 13 to 20% of cases, and it develops from the distal convoluted tubules. This type can be presented in two different forms: Type I, which is sporadic with a favorable prognosis, and Type II, which is hereditary, often bilateral. It is important to remember that pRC tends to be more frequently associated with chronic hemodialysis. Lastly, chromophobe renal cell carcinoma comprises about 5% of cases. This subtype originates from the intercalated cells in the collecting ducts and presents similarities to renal oncocytomas. The importance of identifying these types of tumors on various imaging modalities arises from the fact that imaging is critical for accurately staging renal cell carcinomas and also for operative planning. #kidney #carcinoma #radiology #ct #ctscan #mri #mriscan #educational #poster #healthcare #medical #medicaleducation #nephrology #radiologists #imaging #diagnosticimaging #diagnosis #renal #insights

🔍 A recent study, led by Alisa N. Femia, MD, at NYU Grossman School of Medicine, sheds light on the link between Dermatomyositis (DM) and increased cardiovascular risk. Analyzing data from over 235,000 participants in the All of Us research program, researchers discovered a significant association between DM and cardiovascular comorbidities. The study's methodology included a meticulous cross-sectional analysis, matching DM cases with controls based on various factors like age, sex, race/ethnicity, and health record duration. Participants with DM exhibited a higher prevalence of several cardiovascular conditions, including chronic kidney disease, coronary artery disease, type 2 diabetes, and more, compared to matched controls. The multivariable analysis further confirmed the association between DM and cardiovascular risks, highlighting the increased odds for coronary artery disease, type 2 diabetes, and chronic kidney disease in DM patients. The implications for clinical practice are noteworthy—the findings underscore the importance of screening DM patients for cardiovascular risk factors. Detecting and addressing these factors could potentially mitigate the heightened risk of cardiovascular events and related mortality in individuals with DM. However, it's crucial to note limitations in the study, such as the absence of considerations for how DM treatments might influence cardiovascular disease development and potential inaccuracies or omissions in electronic health records (EHRs). The study was supported by the National Center for Advancing Translational Sciences, NIH. While some authors disclosed consulting fees from pharmaceutical companies, others reported no conflicts of interest. For deeper insights, check out the study published online on December 29, 2023, in the Journal of the American Academy of Dermatology. #Dermatomyositis #CardiovascularHealth #ResearchUpdate https://lnkd.in/gYe-ykF7

‘World’s First Genetically-Edited Pig Kidney Transplant into Living Recipient Performed at Massachusetts General Hospital’ “Today, Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health care system, announced the world’s first successful transplant of a genetically-edited pig (porcine) kidney into a 62-year-old man living with end-stage kidney disease (ESKD). Surgeons from the Mass General Transplant Center conducted the four-hour-long surgery on Saturday, March 16. The procedure marks a major milestone in the quest to provide more readily available organs to patients. Mass General Brigham is an internationally recognized leader in transplantation services, providing advanced care for a wide spectrum of organ and tissue transplants throughout its renowned academic medical system. Under the leadership of Leonardo V. Riella, MD, PhD, Medical Director for Kidney Transplantation, Tatsuo Kawai, MD, PhD, Director of the Legorreta Center for Clinical Transplant Tolerance, along with Nahel Elias, MD, Interim Chief of Transplant Surgery and Surgical Director for Kidney Transplantation, a genetically-edited pig kidney with 69 genomic edits was successfully transplanted into a living patient.” https://lnkd.in/eBY2pxXA #geneediting #genetherapy #innovation #science #technology #healthcare #lifesciences #stem #biotech #pharma #healthcare

We invite you to join our 32nd journal club, which will take place on Wednesday, September 18, 2024 at 8PM EST. Article: Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review & Meta-Analysis Presenters: Frida Velcani (M4) and Xhulio Arolli (M3) Moderator: Tedi Begaj, MD Please RSVP using the link below to receive the Zoom link: https://lnkd.in/ePZ63EW7 Xhulio Arolli is a third-year medical student at Loyola Stritch School of Medicine in Chicago, Illinois, and is interested in pursuing a career in ophthalmology. He also completed his Bachelor’s and Master’s degrees in Biochemistry at Loyola. Originally from Pogradec, Xhulio immigrated to the USA in 2004 to Chicago with his family and recalls his family’s struggle with finding Albanian translation or representation in the healthcare system. As a result, Xhulio feels passionately about being a reliable physician for all the Albanian communities scattered throughout Chicago. Similarly, he aims to continue to help AAMS build a broad social network for Albanian healthcare professionals across the country. Frida Velcani is a fourth-year MD/MBA student at the Geisel School of Medicine at Dartmouth. She graduated from Vassar College Phi Beta Kappa with a degree in Science, Technology, & Society and a minor in Hispanic Studies. Frida went on to work for The diaTribe Foundation, where she co-led a multi-stakeholder initiative focused on improving standards of care in diabetes care. Frida has applied these learnings to support underserved communities in the Upper Valley of New Hampshire/Vermont and promote screening for diabetes-related eye conditions. Frida’s interests also include regulation of therapeutics and medical devices, with experience reporting on critical news events such as the Carbapenem-resistant Pseudomonas aeruginosa (VIM-GES-CRPA) outbreak associated with artificial tears. She also formally presented this topic at the Ocular Microbiology and Immunology Group Meeting in 2023. Tedi Begaj, MD is an assistant professor at Oakland University William Beaumont School of Medicine, and both a retina and uveitis specialist at Associated Retinal Consultants (ARC) in Royal Oak, Michigan. He completed his medical training at the University of Massachusetts, and his ophthalmology residency at Massachusetts Eye and Ear – Harvard Medical School in Boston, Massachusetts. After residency, Dr. Begaj completed his vitreoretinal diseases and surgery fellowship at ARC/Beaumont in Royal Oak, Michigan. Additionally, he completed a 6-month fellowship in uveitis at Northwestern University.

📃Scientific paper: A comparative study of smooth muscle cell characteristics and myofibroblasts in processus vaginalis of pediatric inguinal hernia, hydrocele and undescended testis Abstract: Background Congenital inguinal hernia, hydrocele and undescended testis (UDT) are associated with patent processus vaginalis. The smooth muscles present in the processus vaginalis aid in the descent of the testis and undergo programmed cell death after testicular descent leading to obliteration. The persisting amount of smooth muscle in the processus vaginalis influences the clinical outcome as inguinal hernia, hydrocele or UDT. Therefore, a study was conducted to evaluate the processus vaginalis in these three conditions to observe the presence and phenotype of smooth muscle cells and the presence of myofibroblasts. Materials and methods The processus vaginalis sacs in patients with inguinal hernia, hydrocele and UDT were examined using light microscopy for the presence and distribution of smooth muscle cells and immunohistochemical staining for vimentin, desmin, and α-smooth muscle actin (SMA) to identify the smooth muscle phenotype. Transmission electron microscopy was also performed in all the sacs to observe the presence of myofibroblasts. Results Seventy-eight specimens of processus vaginalis (from seventy-four patients), distributed as 47%, 27%, and 26% as inguinal hernia, hydrocele and UDT respectively, were included in the study. The sacs from inguinal hernia and hydrocele had significantly more presence of smooth muscles distributed as multiple smooth muscle bundles ( p  < 0.001). Desmin and SMA staining of smooth muscle cells was observed in significantly... Continued on ES/IODE ➡️ https://etcse.fr/RTqj ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Happy to share our latest article: 'Advancing Pediatric Sarcomas through Radiomics: A Systematic Review and Prospective Assessment Using Radiomics Quality Score (RQS) and Methodological Radiomics Score (METRICS)'. #PediatricSarcomas #Radiomics #imaging